knowledge -WSS

knowledge

author：hotspot 2025-09-01 15:17:18 - browse：8

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

focus

hotspot

WSS

Florida health officials providing scant details on measles cases

Readout Newsletter: BridgeBio, Akero, and human embryo models

He's 19 months old and has one of the world’s rarest diseases

IVF doctors demand details after CooperSurgical lawsuit

Hospitals owned by private equity see complications spike 25%

Ozempic has benefits for kidney disease as well as diabetes

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

In Spain, a hospital brews its own CAR

As demand for Covid shots wanes, Moderna seeks its next success

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

The high cost of giving birth even with insurance

A new approach to psychiatric drug development

How one medical school became remarkably diverse

Grail spinoff by Illumina should end disastrous merger attempt

Tori Bowie and the unacceptable rates of Black maternal death

Harvard's David Sinclair gets blowback over aging

Wikipedia

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Lack of health data on LGBTQ+ people has serious consequences

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Lack of health data on LGBTQ+ people has serious consequences

Florida health officials providing scant details on measles cases

What STAT readers think about the FDA and patient advocacy

focus

hotspot

leisure time

focus